The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Anti-CD3/CD7 immunotoxins for the treatment of steroid-refractory acute graft-versus-host disease

Nov 12, 2018

Christoph Groth, University Hospital of Muenster, Muenster, Germany, and colleagues conducted a phase I/II trial to evaluate the safety and efficacy of an immunotoxin-combination, a mixture of anti-CD3 and anti-CD7 antibodies separately conjugated to recombinant ricin A (CD3/CD7-IT) for the treatment of patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD). This immunotoxin-combination causes in-vivo depletion of T- and NK-cells and regulates T-cell receptor activation. The findings of this study were publishedahead of print in the Biology of Blood and Marrow Transplantation .

Patients received 4 mg/m 2CD3/CD7-IT in four 4-hour intravenous infusions administered at 48-hour intermissions. GvHD prophylaxis included cyclosporine-A alone or in combination with mycophenolate mofetil. Prophylaxis was continuously administered during treatment with CD3/CD7-IT.

Patient characteristics:

  • N = 20 patients with SR-aGvHD, 85% of these had severe SR-aGvHD
  • Median age: 53 years (range, 18–74)
  • All patients had visceral organ involvement:
    • N = 18 gastrointestinal (GI)
    • N = 5 liver (25%) involvement

Key findings:

  • Median follow-up: 292 days (range, 3–889)
  • Two patients died of disease progression before completing treatment
  • N = 18 patients (90%) received all four scheduled doses of therapy
  • Overall response rate: 60% (95% CI, 36–81%)
  • Complete response rate: 50% (95% CI, 27–73%)
  • 6-month overall survival rate: 60% (95% CI, 36–78%)
  • Eight patients died on trial due to refractory aGvHD (4 patients), refractory GvHD with infection (3 patients), and pseudomembranous colitis (1 patient)
  • Treatment-related AEs included hypoalbuminemia, microangiopathy, and thrombocytopenia
  • One-week treatment course led to T- and NK-cell depletion with rapid recovery of the immune system

This study indicates that CD3/CD7-IT is safe with “relatively low prevalence of manageable and reversible adverse events, primarily worsening of hypoalbuminemia, microangiopathy, and thrombocytopenia” for SR-aGvHD patients. Furthermore, this data suggests that CD3/CD7-IT is a promising treatment option for patients with SR-aGvHD.

  1. Groth C. et al. Phase I/II trial of a combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant.2018 Nov 3. DOI: 1016/j.bbmt.2018.10.020. [Epub ahead of print].